Categories: News

Health Fidelity Celebrates 5 Years of NLP Powered Clinical Suspects, 10 Years of Risk Adjustment

SAN MATEO, Calif.–(BUSINESS WIRE)–#NLP–For Health Fidelity Inc., a company that provides innovative technologies for the value-based care era, 2021 marks the 10th anniversary since incorporation and five years of delivering NLP-derived clinical suspecting, a newer application of the company’s NLP technology.


Health Fidelity was one of the first technology partners that deployed a natural language processor (NLP) engine to support complete and accurate retrospective risk adjustment through the addition of otherwise nearly unreachable unstructured clinical data. Over the past decade, that engine, today known as Lumanent® Insights, has:

  • Supported 9.5+ million lives,
  • Processed 139.2+ million clinical records,
  • Suggested the accurate risk adjustment category more than 95% of the time.

Given the success of applying Lumanent Insights to risk adjustment at 6 of the 10 largest provider sponsored plans in the US, Health Fidelity expanded the use of its NLP to add prospective risk adjustment, deriving clinical suspects, in late 2015. In the half-decade since, Health Fidelity’s clinical suspecting has yielded 25% more confirmed conditions with 10% greater RAF value over structured-data counterparts for its partners. In circumstances where NLP suspects are integrated with traditional risk analytics sources, EHR problem lists or health plan claims data, the acceptance rate further improves, deepening the utility of existing resources.

CEO Steve Whitehurst observed, “At its core, risk adjustment requires a full understanding of everything a patient is going through medically. Healthcare as an industry excels at gathering data. Putting that data to work is a different story.” He continued, “Five years ago, we began leveraging NLP technology to meet the advancing need to completely capture risk at various points of the patient continuum, so our partners can proactively find conditions that may need more rigorous care in a way that lifts, rather than burdens, providers.”

Today, Lumanent Suspects can be incorporated into various Lumanent® workflow modules, from Pre-Encounter Prep to Retrospective Review, and is currently embedded in other market leading population health and point of care platforms too. Through these diverse channels, Lumanent Suspects is delivering value at 4 out of the top 10 non-profit health systems in the United States.

The success of Lumanent Insights begins with Dr. Carol Friedman, a professor of the Department of Biomedical Informatics at Columbia University and a Morris F. Collen Award winner. Since partnering with Health Fidelity in 2011, Dr. Friedman has overseen the NLP engine’s development and maturity. It continues to benefit from her ongoing research; its robustness, when compared to other NLP engines that were rushed to market, is attributed to its blend of clinical specificity and general linguistics applicability. She notes, “We built it to benefit from, and amplify, human expertise and to recognize general medical language patterns. As a result, it understands clinical language and how it’s used, even as physician notes and health care facilities change, without having to be retrained. Lumanent Insights is still the best at what it does.”

To learn more, follow @healthfidelity on Twitter or visit our website, healthfidelity.com.

About Health Fidelity

Health Fidelity simplifies risk adjustment, offering risk-bearing organizations clear visibility into and control over the process. Through our NLP-powered solutions and expert advisory services, we uncover insights that enable better care plans and more complete revenue capture. The Lumanent® suite gives our partners the confidence to pursue and ability to succeed in risk-sharing arrangements across MA, ACA, Medicaid, and ACO programs.

Health Fidelity is a registered trademark of Health Fidelity, Inc.

Contacts

Drew Muldowney

Drew.muldowney@healthfidelity.com
(847)-533-1042

Staff

Recent Posts

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities

Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces…

46 minutes ago

XRP Healthcare® Secures Global Trademark Protection at the Intersection of Healthcare Services and XRP-Powered Payments

Multi-jurisdiction trademark coverage reinforces XRP Healthcare's position across digital health, pharmacy networks, and XRP-based payment…

2 hours ago

Black Book Poll: “Governed AI” Emerges as the Deciding Factor in 2026 NHS Procurement

Respondents report approvals and evaluation readiness are now the bottlenecks driving demand for reusable safety…

2 hours ago

Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares

LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the…

2 hours ago

What Is the Best GLP-1 Supplement for Weight Loss? Industry Analysis Reveals Probiotic Akkermansia Formulas as Affordable Ozempic Alternatives

Health Journey Addresses 'Best GLP-1 Supplement' Question with Akkermansia-Based Formula Analysis as Six-Month Costs Compare…

23 hours ago